Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$10.39 -1.0%	$10.40	$3.85 ▼ $12.43	$1.58B	1.83	1.65 million shs	1.44 million shs
AMLX Amylyx Pharmaceuticals	$8.34 +0.7%	$5.88	$1.76 ▼ $8.59	$743.44M	-0.49	1.15 million shs	1.13 million shs
AMPH Amphastar Pharmaceuticals	$20.62 -5.0%	$24.23	$20.43 ▼ $53.96	$972.01M	0.72	500,236 shs	430,242 shs
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	-1.05%	-12.10%	-0.76%	+41.75%	+138.85%
AMLX Amylyx Pharmaceuticals	+0.72%	+8.59%	+63.53%	+109.55%	+293.40%
AMPH Amphastar Pharmaceuticals	-4.98%	-4.80%	-18.63%	-11.69%	-47.69%
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	+1.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.7818 of 5 stars	1.4	1.0	0.0	4.2	2.4	2.5	0.6
AMLX Amylyx Pharmaceuticals	3.2788 of 5 stars	4.5	1.0	0.0	0.0	2.5	2.5	0.6
AMPH Amphastar Pharmaceuticals	4.2755 of 5 stars	3.1	2.0	0.0	3.7	1.7	4.2	1.3
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.86	Moderate Buy	$10.57	1.75% Upside
AMLX Amylyx Pharmaceuticals	3.00	Buy	$11.75	40.89% Upside
AMPH Amphastar Pharmaceuticals	2.25	Hold	$32.33	56.81% Upside
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AMLX, CALT, AMPH, and ADPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	AMLX Amylyx Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00
6/24/2025	AMLX Amylyx Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$17.00
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/17/2025	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
5/30/2025	AMLX Amylyx Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/14/2025	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$7.00 ➝ $8.00
5/12/2025	AMPH Amphastar Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$45.00 ➝ $30.00
5/9/2025	AMLX Amylyx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $16.00
5/8/2025	AMPH Amphastar Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $35.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	8.82	N/A	N/A	$1.37 per share	7.58
AMLX Amylyx Pharmaceuticals	$87.37M	8.51	N/A	N/A	$2.40 per share	3.48
AMPH Amphastar Pharmaceuticals	$731.97M	1.33	$5.00 per share	4.12	$15.23 per share	1.35
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-74.84%	-62.79%	-24.55%	8/5/2025 (Estimated)
AMLX Amylyx Pharmaceuticals	-$301.74M	-$3.11	N/A	N/A	N/A	N/A	-77.21%	-63.84%	8/6/2025 (Estimated)
AMPH Amphastar Pharmaceuticals	$159.52M	$2.76	7.47	6.27	5.37	19.38%	22.20%	10.40%	8/6/2025 (Estimated)
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A

Latest AMLX, CALT, AMPH, and ADPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AMLX Amylyx Pharmaceuticals	-$0.43	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	AMPH Amphastar Pharmaceuticals	$0.71	N/A	N/A	N/A	$173.42 million	N/A
8/5/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	AMLX Amylyx Pharmaceuticals	-$0.45	-$0.42	+$0.03	-$0.42	N/A	N/A
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.92	2.82
AMLX Amylyx Pharmaceuticals	N/A	12.05	12.05
AMPH Amphastar Pharmaceuticals	0.80	2.95	2.02
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
AMLX Amylyx Pharmaceuticals	95.84%
AMPH Amphastar Pharmaceuticals	65.09%
CALT Calliditas Therapeutics AB (publ)	2.83%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
AMLX Amylyx Pharmaceuticals	11.70%
AMPH Amphastar Pharmaceuticals	27.50%
CALT Calliditas Therapeutics AB (publ)	2.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	142.19 million	Optionable
AMLX Amylyx Pharmaceuticals	200	89.14 million	78.71 million	Optionable
AMPH Amphastar Pharmaceuticals	2,028	47.14 million	34.18 million	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable

AMLX, CALT, AMPH, and ADPT Headlines

Recent News About These Companies

Calliditas hits $90m jackpot as biotech IPO craze continues

February 17, 2025 | pharmaphorum.comP

Calliditas Therapeutics to Present Four Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

October 17, 2024 | tmcnet.com

Calliditas Therapeutics (NASDAQ:CALT) Stock Quotes, Forecast and News Summary

October 4, 2024 | benzinga.com

Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm

September 16, 2024 | prnewswire.com

Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)

September 3, 2024 | prnewswire.com

Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

September 3, 2024 | prnewswire.com

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Q2 2024 Earnings Call Transcript

August 14, 2024 | msn.com

Calliditas Therapeutics AB (publ) (CALT) Q2 2024 Earnings Call Transcript

August 13, 2024 | seekingalpha.com

Calliditas Therapeutics (spons ADRs) earnings: here's what Wall Street expects

August 13, 2024 | markets.businessinsider.com

Calliditas Interim Report January to June 2024

August 13, 2024 | prnewswire.com

LC8.SG,0P0001K80V,0 (LC8.SG)

August 12, 2024 | ca.finance.yahoo.com

Calliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leadership Conference

August 1, 2024 | markets.businessinsider.com

Number of shares and votes in Calliditas Therapeutics

July 31, 2024 | prnewswire.com

(CALT) Trading Advice

July 30, 2024 | news.stocktradersdaily.comN

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, CALT on Behalf of Shareholders

July 28, 2024 | accesswire.comA

STOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger and its Tender Offer for Calliditas Therapeutics AB – CALT

July 27, 2024 | globenewswire.com

STOCKHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring August 30, 2024, for shares of Calliditas Therapeutics AB - CALT

July 26, 2024 | prnewswire.com

CALT Aug 2024 40.000 call (CALT240816C00040000)

July 26, 2024 | finance.yahoo.com

Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis

July 26, 2024 | prnewswire.com

Calliditas Therapeutics AB (publ) (LC8A.F)

July 20, 2024 | nz.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX, CALT, AMPH, and ADPT Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$10.39 -0.11 (-1.05%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$10.28 -0.11 (-1.01%)

As of 07/18/2025 07:54 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Amylyx Pharmaceuticals NASDAQ:AMLX

$8.34 +0.06 (+0.72%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$8.39 +0.05 (+0.60%)

As of 07/18/2025 07:03 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Amphastar Pharmaceuticals NASDAQ:AMPH

$20.62 -1.08 (-4.98%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$21.04 +0.42 (+2.04%)

As of 07/18/2025 07:29 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 07/18/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time